Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AMAZON.COM, INC.

(AMZN)
  Report
Delayed Nasdaq  -  04:00 2022-10-03 pm EDT
115.88 USD   +2.55%
05:18pRivian produces over 7,000 vehicles in third quarter, maintains full-year target
RE
04:47pInsider Sell: Amazon
MT
11:34aBofA Securities Adjusts Amazon.com's Price Target to $157 from $170, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

On The Attack: FDA Pursues Online Retail Fulfillment House

08/17/2022 | 02:13am EDT

In an unprecedented move, the U.S. Food and Drug Administration (FDA or Agency) sent a warning letter to Amazon.com, Inc. (Amazon), a fulfillment house, with respect to distributing over-the-counter (OTC) drug products that are in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). We have seen FDA take enforcement actions against companies who introduce violative products into interstate commerce. However, this appears to be the first time that FDA has taken action against an online retail fulfillment house. FDA's actions may be viewed as a signal that the Agency is closely reviewing and evaluating online retail houses for products that raise safety concerns and violate the FD&C Act.

On August 4, 2022, the FDA issued a warning letter to Amazon regarding its distribution of products that violate the FD&C Act. The products at issue are OTC drug products marketed for mole and skin tag removal. As the drug products have not been approved for their marketed use by the FDA, the warning letter states that Amazon is responsible for introducing and delivering into commerce products that are unapproved new drugs, and such activity is a violation of the FD&C Act. While the FDA recognized that Amazon distributed each of the products on behalf of third parties, it noted that distribution was made directly by Amazon to the consumer and that product orders are "fulfilled" by Amazon, with such fulfillment including storage, packing, and shipping.

The FDA also issued warning letters to Ariella Naturals and Justified Laboratories for selling these unapproved drug products for mole and skin tag removal.

In the letter, the FDA stated, "[t]here are no over-the-counter (OTC) drugs that can be legally sold for mole or skin tag removal, and FDA has safety concerns about drugs marketed OTC directly to consumers for these uses." The FDA further stated that moles should be evaluated by health care providers rather than using such OTC products for mole and skin tag removal, which may lead to delayed cancer diagnosis and cancer progression.

In a news release, Donald Ashley, director of the Office of Compliance in the FDA's Center for Drug Evaluation and Research said, "[t]he Agency's rigorous surveillance works to identify threats to public health and stop these products from reaching our communities. This includes where online retailers like Amazon are involved in the interstate sale of unapproved drug products. We will continue to work diligently to ensure that online retailers do not sell products that violate federal law."

Amazon has 15 working days from receipt of the warning letter to respond to FDA explaining the specific steps taken to address the violations. The FDA also stated that failure to adequately address this matter may result in legal action such as seizure and injunction.

Furthermore, in the news release, FDA stated it will continue to use all tools available to protect public health and remove fraudulent or unproven drug products from the U.S. marketplace. These recently issued warning letters may signal a new trend of enforcement actions against retailers, including fulfillment operators, who sell products deemed to be unapproved new drugs by the FDA.

Online retailers should carefully review the products that they offer for sale to insure that the products comply with FDA regulatory requirements.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Devaki Patel
Foley & Lardner
321 North Clark Street, Suite 2800
Chicago
IL 60654-5313
UNITED STATES
Tel: 312832 4500
Fax: 312832 4700
E-mail: info@foley.com
URL: www.foley.com

© Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about AMAZON.COM, INC.
05:18pRivian produces over 7,000 vehicles in third quarter, maintains full-year target
RE
04:47pInsider Sell: Amazon
MT
11:34aBofA Securities Adjusts Amazon.com's Price Target to $157 from $170, Maintains Buy Rati..
MT
10:40aApple, Amazon's Italian Antitrust Fine Reportedly Scrapped by Local Court
MT
10:00aItalian Court Cancels Apple, Amazon Antitrust Fine
DJ
09:40aCarGurus Names Amazon Web Services Cloud Infrastructure Provider
MT
09:17aItalian Court Throws Out $169 Million Antitrust Fine Against Apple, Amazon
MT
10/01Tencent shifts focus to majority deals, overseas gaming assets for growth-sources
RE
09/30Analysis-European telcos set to win fight with Big Tech, could set global agenda
RE
09/30Amazon Launches Live Stream Shopping in India
MT
More news
Analyst Recommendations on AMAZON.COM, INC.
More recommendations
Financials (USD)
Sales 2022 522 B - -
Net income 2022 502 M - -
Net Debt 2022 25 179 M - -
P/E ratio 2022 3 538x
Yield 2022 -
Capitalization 1 151 B 1 151 B -
EV / Sales 2022 2,25x
EV / Sales 2023 1,91x
Nbr of Employees 1 608 000
Free-Float 85,8%
Chart AMAZON.COM, INC.
Duration : Period :
Amazon.com, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMAZON.COM, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 50
Last Close Price 115,88 $
Average target price 173,28 $
Spread / Average Target 49,5%
EPS Revisions
Managers and Directors
Andrew R. Jassy President, Chief Executive Officer & Director
Brian T. Olsavsky Chief Financial Officer & Senior Vice President
Jeffrey P. Bezos Executive Chairman
Patricia Q. Stonesifer Independent Director
Jonathan Jake Rubinstein Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AMAZON.COM, INC.-32.22%1 151 194
JD.COM, INC.-28.21%76 852
COUPANG, INC.-43.26%29 451
JD HEALTH INTERNATIONAL INC.-26.20%18 246
ETSY, INC.-54.27%12 677
MONOTARO CO., LTD.7.19%7 631